U.S. Aesthetic Injectable Market Trends
The U.S. aesthetic injectable market size was estimated at USD 4.1 billion in 2024 and is projected to grow at a CAGR of 11.2% from 2025 to 2030. The U.S. aesthetic injectable industry continues to evolve as consumer expectations shift toward convenience, personalization, and preventative care. The growing popularity of injectables among a broader range of users, along with advances in product design, is changing the way cosmetic treatments are perceived and delivered. In May 2023, Allergan Aesthetics launched Skinvive by Juvederm in the U.S., an intradermal HA-based microdroplet injection designed to improve cheek skin quality by enhancing hydration and smoothness.
A strong preference for non-surgical cosmetic solutions drives the U.S. aesthetic injectable industry. Consumers are increasingly choosing injectables due to their convenience, short recovery time, and ability to deliver natural-looking results. These procedures offer a discreet option for facial rejuvenation without the risks or downtime associated with surgery. The appeal of quick treatments with visible enhancements fits nicely into the lifestyle of professionals and younger individuals seeking subtle improvements. According to the American Society of Plastic Surgeons (ASPS) 2023 data, 1.47 million cosmetic minimally invasive procedures were performed on males, including 526,062 neuromodulator injections and over 232,000 filler treatments. For females, the number reached 19.7 million, with 8.2 million neuromodulator injections and over 5.5 million filler procedures.
Injectable treatments are growing in popularity among men and younger consumers, who view them not just as corrective tools but as a form of proactive self-care. Men are turning to injectables to refine facial features, while individuals in their 20s and 30s often use them to prevent early signs of aging. This shifting demographic has broadened the customer base and encourages providers to tailor services and messaging to a more diverse audience, including those looking for maintenance rather than transformation. In October 2024, Allergan Aesthetics presented new data at the ASDS Annual Meeting in Orlando, Florida, highlighting safety and patient satisfaction with facial injectables. The presentations included diverse patient demographics across the U.S., emphasizing treatment efficacy and social media’s impact on patient expectations.
Ongoing innovation is shaping the competitive edge of the injectable market. New products are designed to last longer, integrate more seamlessly with skin, and provide more natural movement and appearance. These advancements make treatments more appealing to first-time users and returning clients. With the development of differentiated formulations and targeted applications, brands can address specific aesthetic concerns with greater precision and reliability. In January 2025, Galderma announced positive interim results from a U.S.-based trial evaluating Sculptra combined with Restylane for treating facial volume loss caused by medication-driven weight loss. The study showed significant aesthetic improvements and high patient satisfaction. A six-month extension is ongoing to assess long-term effects.
U.S. Aesthetic Injectable Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the U.S. aesthetic injectable market report based on product, application, and end-use:Product Outlook (Revenue, USD Million, 2018 - 2030)
- Hyaluronic Acid (HA)
- Botulinum Toxin (Botox)
- Aquatic Light Injections
- Others
Application Outlook (Revenue, USD Million, 2018 - 2030)
- Facial Line Correction
- Lip Augmentation
- Face Lift
- Acne Scar Treatment
- Lipoatrophy Treatment
- Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Medical Spas
- Dermatology Clinics
- Hospitals
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Aesthetic Injectable Market Variables, Trends & Scope
Chapter 4. U.S. Aesthetic Injectable Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Aesthetic Injectable Market: Application Estimates & Trend Analysis
Chapter 6. U.S. Aesthetic Injectable Market: End Use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Ipsen Pharma
- AbbVie, Inc.
- Merz GmbH and Co. KGaA
- Galderma
- Prollenium Medical Technologies, Inc.
- Tiger Aesthetics Medical, LLC
- Sinclair Pharma
- Medytox, Inc.
- Revance Therapeutics, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | June 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 4.1 Billion |
| Forecasted Market Value ( USD | $ 7.8 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | United States |
| No. of Companies Mentioned | 9 |
